Lung cancer
A study to evaluate immunotherapy pembrolizumab with chemotherapy in lung cancer patient.
Who can joinWomen
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Last updated on the registry 26 May 2025. Please confirm with the hospital that this trial is still taking patients.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial HospitalMumbai, MaharashtraDirections ↗
Registry summary (technical)
Phase 3 randomized study for evaluation of addition of Pembrolizumab to palliative therapy in NSCLC. - NIL
Sponsor: Tata Memorial Hospital
CTRI/2023/08/056715 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 26 May 2025 · read by us 5 Nov 2026